Pet Releaf is the number #1 and most trusted CBD for pets’ company in the world because we control our entire manufacturing process from seed to sale and from plant to pet. We spent years of research and development ensuring that every single part of our production process was safe for pets and that our final products were not only great for their health, but will always be something that we can wholeheartedly stand behind. From seed to sale, from plant to pet you can be confident that Pet Releaf CBD hemp oils for dogs and cats are the safest and most effective option for your pet.  
However, switching to CBD oil from a conventional medication is far from a random stab in the dark. In fact, there was a large scale (and very well-documented) survey carried out less than two years ago that looked at precisely what percentage of patients were able to “swap” their side effect-inducing meds for a 100% natural, cannabis-based therapy.
Third-party testing: Once a CBD oil is manufactured, CBD oil companies will often submit their products for third-party tests, which are conducted by non-company personnel to ensure the product is safe for public consumption and meets quality standards.CBD oils should always be accompanied with information about third-party tests; best practice is to avoid oils that do not supply these details.
Perhaps it’s because many people have romantic and misplaced notions about nature. Some even point out that we come hard-wired with cannabinoid receptors in our brains and they must have a purpose, so why not use them? This is not exactly a persuasive argument: Nature endowed us with our own cannabinoids, so unless you have a deficiency of them or sluggish receptors, you really don’t need supplementation.
In 1988, the first cannabinoid receptor was identified (CB1) (Howlett et al 1988) and in 1993, a second was described (CB2) (Munro et al 1993). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB1 is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord (Herkenham et al 1990; Hohmann et al 1999), as well as the peripheral nervous system (Fox et al 2001; Dogrul et al 2003) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated (Dogrul et al 2003). CB2, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes (Mackie 2006). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain (Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands (“endocannabinoids”) and metabolizing enzymes comprise the endocannabinoid system (ECS) (Di Marzo et al 1998), whose functions have been prosaically termed to be “relax, eat, sleep, forget and protect” (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (Cannabis sativa, C. indica) (THC, CBD and others), opium poppy (Papaver somniferun) (morphine, codeine), chile peppers (eg, Capsicum annuum, C. frutescens, C. chinense) (capsaicin) and willow bark (Salix spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB1 receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see Pacher et al (2006), while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain (Walker and Huang 2002).
So totally blown away by Medterra CBD oil. I have taken other brands and nothing compares to Medterra. I like that it is certified THC free and grown and manufactured right here in the U.S. The shipping was very reasonable and I received my oil within about 4-5 days. They also offer a 30 day money back guarantee if I decide to return. ( but I won’t!!!). You can’t go wrong with Medterra for your joint and body aches. I’m finally able to sleep at night again!! Thank you Medterra !!!!
Some users speculate about appropriate dosages or methods of application—including whether or not a small amount of THC boosts CBD’s effects, or whether different methods of administration lead to quicker or more significant effects. Some CBD producers also claim that it has a cumulative effect, and so needs to be used regularly to produce a benefit. But Grant says it’s tough to say at this point exactly how people should (or shouldn’t) be using CBD.

Due to its high content of omega 3 and omega 6 fatty acids, hemp oil has a composition similar to skin lipids, which makes it an excellent natural emollient and moisturizer. It is especially useful for dry, tired or dehydrated skin and nails. It increases the skin elasticity and water retention capacity in tissues. Pure hemp oil can be used to treat dry hair and is often included in hair conditioners.
As an advocate of industrial hemp, Nutiva Founder John Roulac successfully sued the US Drug Enforcement Administration in 2002 to keep hemp foods legal, paving the way for hemp foods to be sold in the United States. Roulac has authored four books on environmental topics including composting and hemp that have combined sales of over one million copies. With expertise ranging from home composting and natural healing to forestry, hemp agriculture, GMO labeling and organic farming, Roulac has founded five nonprofit ecological groups, one of which, Forests Forever, placed the California Forest Protection Act (Prop 130) on the state ballot in 1990.

Cannabinoids are a class of compounds that interact with receptors throughout your body. CBD is just one of dozens of cannabinoids found in cannabis, including tetrahydrocannabinol (THC), which is the one responsible for marijuana’s famous high. Medical cannabis is technically any cannabis product used for medicinal purposes, and these can contain THC or CBD or both, said Nick Jikomes, a neuroscientist at Leafly, a website that provides information about legal cannabis. “A common mistake people make is to think that CBD is ‘the medical cannabinoid’ and THC is ‘the recreational cannabinoid.’” That’s inaccurate, he said, because THC is a potent anti-inflammatory and can be helpful for pain.
The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms (Nicolodi et al 1998). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release (Shen et al 1996), THC produces 30%–40% reduction in NMDA responses, and THC is a neuroprotective antioxidant (Hampson et al 1998). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide (Richardson et al 1998a). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia (Li et al 1999), and THC will do so at sub-psychoactive doses in experimental animals (Ko and Woods 1999). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production (Manzanares et al 1998), may allow opiate sparing in clinical application (Cichewicz et al 1999), prevents development of tolerance to and withdrawal from opiates (Cichewicz and Welch 2003), and rekindles opiate analgesia after a prior dosage has worn off (Cichewicz and McCarthy 2003). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.

CBD Cream

×